DBV Technologies

DBVTNasdaq France Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$798.182 M

$13.48 -1.89%

Close of 7 Aug 2026

Revenue

$5.64M

#3281 by revenue

Earnings

-$146.9M

Loss-making

Shares outstanding

296,061,497

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#54Aura BiosciencesAURA$826.5M
#55Solid BiosciencesSLDB$826.0M
#56DBV TechnologiesDBVT$798.2M
#57Candel TherapeuticsCADL$775.9M
#58Agomab TherapeuticsAGMB$714.1M

Where these numbers come from

Share counts and financials for DBV Technologies are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.